{"id":4772,"date":"2026-05-06T09:12:32","date_gmt":"2026-05-06T07:12:32","guid":{"rendered":"https:\/\/ksbbiotech.com\/?page_id=4772"},"modified":"2026-06-01T17:25:27","modified_gmt":"2026-06-01T15:25:27","slug":"ck-mb","status":"publish","type":"page","link":"https:\/\/ksbbiotech.com\/zh\/ck-mb\/","title":{"rendered":"\u808c\u9178\u6fc0\u9176\u540c\u5de5\u9176MB\uff08CK-MB\uff09"},"content":{"rendered":"\t\t
PDB ID: 1I0E. Source: RCSB Protein Data Bank. For illustration purposes only.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
The VeriLumenTM<\/sup> CK-MB Rapid Test is a fluorescence immunochromatographic assay for the quantitative detection of creatine kinase-MB (CK-MB) in human whole blood, plasma, or serum samples. CK-MB is a cardiac-specific enzyme released into the bloodstream following myocardial injury and is widely used as a biomarker in the clinical assessment of suspected acute myocardial infarction (AMI). The assay provides rapid quantitative results to support timely evaluation in laboratory and point-of-care settings.<\/p> This test supports the clinical assessment and auxiliary diagnosis of myocardial infarction, as well as the evaluation of myopathy and related conditions. Quantitative CK-MB measurement may help healthcare professionals detect myocardial injury and monitor disease progression when interpreted together with clinical findings and other diagnostic information.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t